Key Stats for Pfizer Stock
- Current Price: $27.93
- Target Price (Mid): ~$29
- Street Target: ~$29
- Potential Total Return: ~5%
- Annualized IRR: ~1.2% / year
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free) >>>
What Happened?
Pfizer (PFE) trades at $27.93, about 4% below its 52-week high and yielding more than 6%, yet the market still values it as though the next five years hold almost no annual return. On September 22, the company’s international commercial chief gave the most concrete account yet of why that view might be wrong, and the gap between his story and the stock’s price is the reason to look closely.
The stock is up roughly 12% this year, but investors searching for Pfizer this week were not chasing a spike. They were asking whether a company that has gone nowhere for years, held up by its dividend, has a real growth engine underneath. Management insists it does. TIKR’s valuation model suggests the market is not yet willing to pay for it.
The International Engine Went From $0.5 Billion to $4 Billion
Speaking at a JPMorgan conference on September 22, Alexandre de Germay, Pfizer’s EVP and Chief International Commercial Officer, put a figure on the rebuild most investors have missed. In his international business specifically, new and newly acquired products generated roughly $0.5 billion in 2023. They now do about $4 billion. Over the same stretch, the productivity of the international sales force tripled, the result of pulling money out of unproductive launches and concentrating it where the top four countries drive 40% of the international book.
That mechanism showed up globally in the second quarter. Pfizer’s launch and acquired portfolio generated $3.2 billion worldwide in Q2, growing 18% after a 22% gain in Q1, per the company’s earnings materials. De Germay framed the total new and acquired base at roughly $13 billion in annualized revenue, a base that barely existed three years ago and is growing while the pandemic franchise fades.
The vaccine runway he described is what the model treats most conservatively. In older adults, Pfizer has vaccinated only about 25% of the targeted 65-and-over population in France, 28% in Germany, and 3% in Japan for its Prevnar and ABRYSVO franchises. Those markets are barely tapped, and LORBRENA shows what conversion looks like: now roughly a $1 billion product, it holds 77% first-line share in France.
See historical and forward estimates for Pfizer stock (It’s free!) >>>
The Cliff That Keeps the Stock Cheap
Eliquis, Pfizer’s largest franchise, loses U.S. exclusivity around 2028. Pfizer’s Q2 10-Q guides to an unfavorable revenue impact from loss of exclusivity of about $1.1 billion in 2026, and the company expects that impact to accelerate sharply over the following two years, with CEO Albert Bourla warning of a modest company decline in 2028 before growth resumes in 2029. Products losing patent protection in 2026 and 2027 generated about $21.4 billion in 2024 sales, close to a third of revenue.
That is why consensus points to a slight revenue decline, and why the stock trades near 10 times forward earnings, well under peers. Johnson & Johnson trades around 24 times and Novartis around 15, per TIKR data, so the discount is real and reflects genuine doubt about 2028. The question is whether de Germay’s commercial rebuild, plus obesity and oncology, turns a flat base into growth or merely holds the line.
Obesity is the swing factor management leans on hardest. De Germay sees a market reaching $120 billion to $150 billion by 2030, fragmenting into many segments rather than one. Pfizer’s berobenatide, acquired in the Metsera deal that closed in November 2025 for about $7 billion upfront and up to roughly $10 billion with milestones, sits in Phase 3, with an amylin combination reading out at year-end. Management suggests that combo could offer a differentiated monthly option for higher-severity patients, though the trial has not yet read out, and analysts at Guggenheim called the earlier berobenatide data solid but relatively undifferentiated from what is already on the market.
See how Pfizer performs against its peers in TIKR (It’s free!) >>>
TIKR Advanced Model Analysis
- Current Price: $27.93
- Target Price (Mid): ~$29
- Potential Total Return: ~5%
- Annualized IRR: ~1.2% / year
See analysts’ growth forecasts and price targets for Pfizer stock (It’s free!) >>>
The model entry price of $27.74 sits just below the live quote. The two revenue drivers behind any upside are the launch and acquired portfolio, led by Seagen oncology and products like LORBRENA, and the vaccine penetration runway in under-vaccinated developed markets. The margin driver is Pfizer’s cost program, which has stripped significant operating expense out of an organization that management conceded was spending inefficiently. The primary risk is the Eliquis cliff arriving before the new engine and obesity pipeline can carry the top line.
The upside: if berobenatide and oncology convert, the flat base the model assumes becomes real growth, and a re-rating from 10 times earnings does the rest. The downside: the cliff bites in 2027 and 2028 faster than the new products ramp, leaving the 6% yield as the only support.
Conclusion
The next real test comes at year-end, when the berobenatide amylin combination reads out. That single data set will settle more of the Pfizer debate than any quarter of earnings. A clean win gives the market its first hard reason to price the obesity franchise as a growth driver rather than a hope, and de Germay’s commercial rebuild suddenly has a product worth deploying against. A muddy result leaves the stock where it is: near its highs, yielding 6%, and waiting on 2028.
See what stocks billionaire investors are buying so you can follow the smart money with TIKR.
Should You Invest in Pfizer?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Pfizer, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Pfizer alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
